Skip to main content
    A

    Axsome Therapeutics Inc (AXSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $135.95
    -1.06 (-0.77%)

    Market Cap: $7.45B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Axsome Therapeutics Inc (AXSM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Axsome Therapeutics (AXSM) has a market cap of $7.45B and an enterprise value of $7.35B. Revenue grew 54.16% over the last 12 months from the 12 months before. Its share count is up 4.84% from a year earlier.

    Total Valuation

    Enterprise value is 1.41% below the market cap, as cash exceeds debt.

    Market Cap$7.45B
    Enterprise Value$7.35B
    Latest price (Nov 17, 2026)$135.95

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.25% in the quarter ended Sep 30, 2026 and grew 4.38% a year over 2 years.

    Shares Outstanding52.45M
    Shares Change (YoY)+4.84%
    Shares Change (QoQ)+1.25%
    Share Count Growth (2Y CAGR)+4.38%

    Valuation Ratios

    Sales and book value multiples are 8.2x and 67.6x. Its year-end P/S ranged from 10.5x to 64.8x from 2022 to 2025.

    P/S Ratio8.2x
    Forward P/S7.8x
    P/B Ratio67.6x
    P/TBV Ratio123.7x

    Valuation history and multiples

    Price Statistics

    The stock is down 2.68% over 52 weeks and trades 19.37% below its 50-day average.

    Beta (1Y)0.72
    52-Week Change-2.68%
    1-Month Change-12.75%
    3-Month Change-37.69%
    6-Month Change-40.02%
    5-Year Change+275.14%
    10-Year Change+2055.67%
    Total Return (1Y)-2.68%
    Total Return (3Y CAGR)+31.42%
    Total Return (5Y CAGR)+30.76%
    Return vs SPY (1Y)-19.38%
    Max Drawdown (1Y)-49.13%
    Max Drawdown (3Y)-49.13%
    Sharpe Ratio (1Y)-0.18
    Correlation with SPY (1Y)0.22
    50-Day Average$168.62
    200-Day Average$196.56
    52-Week Range$123.00 to $260.19
    RSI (14 Days)36.6
    Average Volume (20 Days)1.14M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.42x current liabilities, and total debt is 1.98x shareholder equity.

    Current Ratio1.42x
    Quick Ratio1.34x
    Debt / Equity1.98x

    Returns and Efficiency

    Return on invested capital is -48.11% over the last 12 months, against a 5-year average of -90.61%.

    Return on Equity (ROE)-149.19%
    Return on Assets (ROA)-19.02%
    Return on Invested Capital (ROIC)-48.11%
    Return on Capital Employed (ROCE)-47.63%
    ROA (5Y Average)-64.55%
    ROIC (5Y Average)-90.61%
    Asset Turnover1.16x
    Inventory Turnover1.45x
    Receivables Turnover2.79x
    Cash Conversion Cycle-2137 days

    Scores

    AXSM has an Altman Z-Score of 4.26, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score4.26
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $865.27M over the last 12 months.

    Revenue$865.27M
    Revenue Growth (YoY)+54.16%
    Gross Profit$806.85M
    Operating Income-$151.03M
    Pretax Income-$156.65M
    Net Income-$157.29M
    EBITDA-$139.79M
    EBIT-$151.03M
    Reported EPS (TTM)-$3.06

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 12.75% of the $826.77M in total assets.

    Cash and Equivalents$313.86M
    Total Debt$208.49M
    Net Cash$105.37M
    Net Cash Per Share$2.01
    Working Capital$214.92M
    Shareholder Equity$105.43M
    Book Value Per Share$2.01
    Tangible Book Value$57.64M
    Tangible Book Per Share$1.10
    Total Assets$826.77M
    Total Liabilities$721.34M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $839.00K of capital spending, operating cash flow left -$82.61M of free cash flow.

    Operating Cash Flow-$81.77M
    Capital Expenditures$839.00K
    Free Cash Flow-$82.61M
    FCF Per Share-$1.58
    Depreciation and Amortization$11.24M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -17.45%.

    Gross Margin93.25%
    Operating Margin-17.45%
    Pretax Margin-18.10%
    Net Margin-18.18%
    EBITDA Margin-16.16%
    EBIT Margin-17.45%
    FCF Margin-9.55%

    Growth

    Revenue grew 133.68% a year over 3 years.

    Revenue Growth (3Y CAGR)+133.68%
    Book Value Per Share Growth (2Y CAGR)-34.26%
    Tangible Book Per Share Growth (2Y CAGR)-48.44%

    Revenue and profit by year

    Dividends and Yields

    AXSM does not pay a dividend. Its free cash flow yield is -1.16%.

    FCF Yield-1.16%
    Buyback Yield-1.44%
    Shareholder Yield-1.44%

    Peer Position

    Against 3 similar companies, AXSM has the 3rd highest P/S.

    P/S Ratio8.2x vs 11.1x median
    ROIC-48.11% vs -74.31% median
    Revenue Growth (Trailing 4 Quarters, YoY)+54.16% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 50.66% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+50.66%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About AXSM

    What is AXSM's market cap?

    Axsome Therapeutics has a market cap of $7.45B. Its enterprise value, which adds debt and subtracts cash, is $7.35B.

    How many shares of AXSM are outstanding?

    Axsome Therapeutics has 52.45M shares outstanding. The count is up 4.84% from a year earlier.

    Does AXSM pay a dividend?

    No. Axsome Therapeutics does not pay a dividend.

    How much debt does AXSM have?

    Axsome Therapeutics has $208.49M of total debt and $313.86M of cash and equivalents, a net cash position of $105.37M.